TY - JOUR
T1 - Breast MRI in patients after breast conserving surgery with sentinel node procedure using a superparamagnetic tracer
AU - Christenhusz, Anke
AU - Pouw, Joost J.
AU - Simonis, Frank F.J.
AU - Douek, Michael
AU - Ahmed, Muneer
AU - Klaase, Joost M.
AU - Dassen, Anneriet E.
AU - Klazen, Caroline A.H.
AU - van der Schaaf, Margreet C.
AU - ten Haken, Bernard
AU - Alic, Lejla
N1 - Funding Information:
This study has received funding by the EU Interreg Deutschland Nederland Program and the Dutch Technology Foundation STW.
Publisher Copyright:
© 2021, The Author(s) under exclusive licence to European Society of Radiology.
Financial transaction number:
342163149
PY - 2022/1/27
Y1 - 2022/1/27
N2 - Background: A procedure for sentinel lymph node biopsy (SLNB) using superparamagnetic iron-oxide (SPIO) nanoparticles and intraoperative sentinel lymph node (SLN) detection was developed to overcome drawbacks associated with the current standard-of-care SLNB. However, residual SPIO nanoparticles can result in void artefacts at follow-up magnetic resonance imaging (MRI) scans. We present a grading protocol to quantitatively assess the severity of these artefacts and offer an option to minimise the impact of SPIO nanoparticles on diagnostic imaging. Methods: Follow-up mammography and MRI of two patient groups after a magnetic SLNB were included in the study. They received a 2-mL subareolar dose of SPIO (high-dose, HD) or a 0.1-mL intratumoural dose of SPIO (low-dose, LD). Follow-up mammography and MRI after magnetic SLNB were acquired within 4 years after breast conserving surgery (BCS). Two radiologists with over 10-year experience in breast imaging assessed the images and analysed the void artefacts and their impact on diagnostic follow-up. Results: A total of 19 patients were included (HD, n = 13; LD, n = 6). In the HD group, 9/13 patients displayed an artefact on T1-weighted images up to 3.6 years after the procedure, while no impact of the SPIO remnants was observed in the LD group. Conclusions: SLNB using a 2-mL subareolar dose of magnetic tracer in patients undergoing BCS resulted in residual artefacts in the breast in the majority of patients, which may hamper follow-up MRI. This can be avoided by using a 0.1-mL intratumoural dose.
AB - Background: A procedure for sentinel lymph node biopsy (SLNB) using superparamagnetic iron-oxide (SPIO) nanoparticles and intraoperative sentinel lymph node (SLN) detection was developed to overcome drawbacks associated with the current standard-of-care SLNB. However, residual SPIO nanoparticles can result in void artefacts at follow-up magnetic resonance imaging (MRI) scans. We present a grading protocol to quantitatively assess the severity of these artefacts and offer an option to minimise the impact of SPIO nanoparticles on diagnostic imaging. Methods: Follow-up mammography and MRI of two patient groups after a magnetic SLNB were included in the study. They received a 2-mL subareolar dose of SPIO (high-dose, HD) or a 0.1-mL intratumoural dose of SPIO (low-dose, LD). Follow-up mammography and MRI after magnetic SLNB were acquired within 4 years after breast conserving surgery (BCS). Two radiologists with over 10-year experience in breast imaging assessed the images and analysed the void artefacts and their impact on diagnostic follow-up. Results: A total of 19 patients were included (HD, n = 13; LD, n = 6). In the HD group, 9/13 patients displayed an artefact on T1-weighted images up to 3.6 years after the procedure, while no impact of the SPIO remnants was observed in the LD group. Conclusions: SLNB using a 2-mL subareolar dose of magnetic tracer in patients undergoing BCS resulted in residual artefacts in the breast in the majority of patients, which may hamper follow-up MRI. This can be avoided by using a 0.1-mL intratumoural dose.
KW - Artefacts
KW - Breast cancer
KW - Magnetic resonance imaging
KW - Sentinel lymph node biopsy
KW - Superparamagnetic iron oxide nanoparticles
KW - UT-Gold-D
UR - http://www.scopus.com/inward/record.url?scp=85123798716&partnerID=8YFLogxK
U2 - 10.1186/s41747-021-00257-7
DO - 10.1186/s41747-021-00257-7
M3 - Article
C2 - 35083595
AN - SCOPUS:85123798716
SN - 2509-9280
VL - 6
JO - European radiology experimental
JF - European radiology experimental
IS - 1
M1 - 3
ER -
